Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9Y3C8
UPID:
UFC1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y3C8; A8K9R1; D3DVF9; Q549X0; Q5VTX1; Q9BS96; Q9P009
Background:
Ubiquitin-fold modifier-conjugating enzyme 1 plays a pivotal role in the process of ufmylation, a post-translational modification involving the ubiquitin-like modifier UFM1. This enzyme acts as an E2 conjugating enzyme, accepting UFM1 from the E1 enzyme UBA5, and is crucial for the maintenance of cellular homeostasis, particularly in response to endoplasmic reticulum stress.
Therapeutic significance:
The enzyme's involvement in neurodevelopmental disorder with spasticity and poor growth highlights its potential as a target for therapeutic intervention. Understanding the role of Ubiquitin-fold modifier-conjugating enzyme 1 could open doors to potential therapeutic strategies, offering hope for patients suffering from this debilitating condition.